GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Shiller PE Ratio

ANIX (Anixa Biosciences) Shiller PE Ratio : (As of Apr. 28, 2025)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anixa Biosciences Shiller PE Ratio Historical Data

The historical data trend for Anixa Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Shiller PE Ratio Chart

Anixa Biosciences Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anixa Biosciences Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anixa Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Anixa Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Shiller PE Ratio falls into.


;
;

Anixa Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Anixa Biosciences's E10 for the quarter that ended in Jan. 2025 is calculated as:

For example, Anixa Biosciences's adjusted earnings per share data for the three months ended in Jan. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=-0.1/134.0288*134.0288
=-0.100

Current CPI (Jan. 2025) = 134.0288.

Anixa Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201504 -0.237 99.824 -0.318
201507 -0.164 100.691 -0.218
201510 -0.137 100.346 -0.183
201601 -0.164 99.957 -0.220
201604 -0.150 100.947 -0.199
201607 -0.130 101.524 -0.172
201610 -0.120 101.988 -0.158
201701 -0.410 102.456 -0.536
201704 0.020 103.167 0.026
201707 -0.120 103.278 -0.156
201710 -0.110 104.070 -0.142
201801 -0.110 104.578 -0.141
201804 -0.080 105.708 -0.101
201807 -0.300 106.324 -0.378
201810 -0.290 106.695 -0.364
201901 -0.250 106.200 -0.316
201904 -0.130 107.818 -0.162
201907 -0.110 108.250 -0.136
201910 -0.100 108.577 -0.123
202001 -0.130 108.841 -0.160
202004 -0.120 108.173 -0.149
202007 -0.110 109.318 -0.135
202010 -0.090 109.861 -0.110
202101 -0.090 110.364 -0.109
202104 -0.080 112.673 -0.095
202107 -0.140 115.183 -0.163
202110 -0.130 116.696 -0.149
202201 -0.130 118.619 -0.147
202204 -0.120 121.978 -0.132
202207 -0.090 125.002 -0.096
202210 -0.120 125.734 -0.128
202301 -0.080 126.223 -0.085
202304 -0.070 127.992 -0.073
202307 -0.080 128.974 -0.083
202310 -0.090 129.810 -0.093
202401 -0.100 130.124 -0.103
202404 -0.100 132.289 -0.101
202407 -0.100 132.708 -0.101
202410 -0.090 133.182 -0.091
202501 -0.100 134.029 -0.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anixa Biosciences  (NAS:ANIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Anixa Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences Business Description

Traded in Other Exchanges
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747

Anixa Biosciences Headlines

From GuruFocus